PRECISION Regulatory Wednesday, May 27, 2026 +0.85 Positive

PBGENE-HBV shows first clinical evidence of cccDNA elimination in hepatitis B patients

Precision BioSciences announced late-breaking clinical data from the ELIMINATE-B study demonstrating that PBGENE-HBV directly eliminated cccDNA with a 10-fold reduction in viral transcripts and achieved pgRNA loss in 100% of treated patients. The data represent a potential breakthrough in hepatitis B treatment by directly targeting the virus's root cause rather than providing lifelong suppression.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day